688238 和元生物
午间休市 12-22 11:29:42
资讯
新帖
简况
机构密集调研存储芯片！券商展望2026年：科技或仍是最强主线
券商中国 · 12-12
机构密集调研存储芯片！券商展望2026年：科技或仍是最强主线
和元生物（688238）新增【基因编辑】概念
证券之星 · 11-17
和元生物（688238）新增【基因编辑】概念
每周股票复盘：和元生物（688238）补选杨兴林为非独立董事
证券之星 · 11-16
每周股票复盘：和元生物（688238）补选杨兴林为非独立董事
和元生物（688238）披露补选董事会成员及变更独立董事公告，11月13日股价上涨1.56%
证券之星 · 11-13
和元生物（688238）披露补选董事会成员及变更独立董事公告，11月13日股价上涨1.56%
每周股票复盘：和元生物（688238）将补选董事及独董
证券之星 · 11-09
每周股票复盘：和元生物（688238）将补选董事及独董
【机构调研记录】南华基金调研和元生物
证券之星 · 11-06
【机构调研记录】南华基金调研和元生物
【私募调研记录】域秀资产调研赛恩斯、和元生物
证券之星 · 11-06
【私募调研记录】域秀资产调研赛恩斯、和元生物
和元生物（688238）披露拟补选非独立董事及变更独立董事事项，11月04日股价下跌3.98%
证券之星 · 11-04
和元生物（688238）披露拟补选非独立董事及变更独立董事事项，11月04日股价下跌3.98%
每周股票复盘：和元生物（688238）股东户数增11.44%，三季报营收降14.56%
证券之星 · 11-02
每周股票复盘：和元生物（688238）股东户数增11.44%，三季报营收降14.56%
股市必读：和元生物三季报 - 第三季度单季净利润同比增长24.70%
中金财经 · 10-29
股市必读：和元生物三季报 - 第三季度单季净利润同比增长24.70%
和元生物（688238）2025年三季报简析：亏损收窄，盈利能力上升
证券之星 · 10-29
和元生物（688238）2025年三季报简析：亏损收窄，盈利能力上升
和元生物（688238）披露2025年第三季度报告，10月28日股价下跌0.39%
证券之星 · 10-28
和元生物（688238）披露2025年第三季度报告，10月28日股价下跌0.39%
和元生物(688238)9月30日股东户数1.4万户，较上期增加11.44%
证券之星 · 10-28
和元生物(688238)9月30日股东户数1.4万户，较上期增加11.44%
图解和元生物三季报：第三季度单季净利润同比增长24.70%
证券之星 · 10-28
图解和元生物三季报：第三季度单季净利润同比增长24.70%
【机构调研记录】嘉实基金调研剑桥科技、和元生物等3只个股（附名单）
证券之星 · 09-11
【机构调研记录】嘉实基金调研剑桥科技、和元生物等3只个股（附名单）
【机构调研记录】兴业基金调研和元生物
证券之星 · 09-11
【机构调研记录】兴业基金调研和元生物
9月1日和元生物发布公告，股东减持97万股
证券之星 · 09-01
9月1日和元生物发布公告，股东减持97万股
每周股票复盘：和元生物（688238）上半年营收增6.01%
证券之星 · 08-31
每周股票复盘：和元生物（688238）上半年营收增6.01%
股市必读：和元生物（688238）8月27日披露最新机构调研信息
证券之星 · 08-28
股市必读：和元生物（688238）8月27日披露最新机构调研信息
【机构调研记录】南华基金调研和元生物
证券之星 · 08-27
【机构调研记录】南华基金调研和元生物
暂无数据
公司概况
公司名称：
和元生物技术(上海)股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-03-22
主营业务：
和元生物技术(上海)股份有限公司的主营业务是细胞和基因治疗CRO/CDMO业务。公司的主要产品是基因治疗载体研制服务、基因功能研究服务、基因检测服务、新药Pre-IND服务、新药Post-IND服务、临床III期生产服务、商业化生产服务、Post-IND配套服务、再生医学制备服务、细胞存储及配套服务、生物原料、生物制剂产品、试剂、试剂盒及其他产品。
发行价格：
13.23
{"stockData":{"symbol":"688238","market":"SH","secType":"STK","nameCN":"和元生物","latestPrice":6.88,"timestamp":1766374182000,"preClose":6.87,"halted":0,"volume":3481253,"delay":0,"changeRate":0.0015,"floatShares":641000000,"shares":649000000,"eps":-0.4533,"marketStatus":"午间休市","change":0.01,"latestTime":"12-22 11:29:42","open":6.82,"high":6.94,"low":6.82,"amount":23948100,"amplitude":0.0175,"askPrice":6.88,"askSize":25,"bidPrice":6.87,"bidSize":84,"shortable":0,"etf":0,"ttmEps":-0.4533,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766379600000},"marketStatusCode":3,"adr":0,"adjPreClose":6.87,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766367000000,1766374200000],[1766379600000,1766386800000]],"highLimit":7.56,"lowLimit":6.18,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":649036700,"isCdr":false,"pbRate":3.01,"roa":"--","roe":"--","epsLYR":-0.497,"committee":0.306381,"marketValue":4465000000,"turnoverRate":0.0054,"status":0,"floatMarketCap":4411000000},"requestUrl":"/m/hq/s/688238/tweets","defaultTab":"tweets","newsList":[{"id":"2590527403","title":"机构密集调研存储芯片！券商展望2026年：科技或仍是最强主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2590527403","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590527403?lang=zh_cn&edition=full","pubTime":"2025-12-12 13:25","pubTimestamp":1765517100,"startTime":"0","endTime":"0","summary":" 12月以来，A股市场机构调研活动持续活跃，券商分析师作为调研主力，也在积极进行上市公司的实地走访与交流，挖掘年末布局的方向。 Choice数据显示，本月以来已有超过200家A股上市公司接受了券商调研，电子、机械设备等行业热度高，同时，近期受到热捧的存储芯片概念相关公司被券商密集调研。 临近年末，国金证券、中泰证券等多家券商在本周发布2026年度策略。券商普遍认为，科技板块仍是最看好的明年主线之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2025-12-12/doc-inhapmrm5729848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0005","BK0187","LU1808992512.USD","002975","688238","SGXZ49509284.SGD","688048","301319","SGXZ81163826.USD","BK0170","300476","BK0216","BK0221","LU1969619763.USD","BK0209","BK0143","BK0077","BK0224","LU0469268626.HKD","BK0231","LU1934453819.USD","LU2328871848.SGD","BK0220","600814","688372","SINA","BK0093","688028","BK0214","600487","688691","BK0259","301308","002353","BK0167","BK0188","BK0144","LU1979443071.USD","BK0148","BK0175","BK0070","BK0176","605488","BK0196","BK0197","BK0251","301087","301468"],"gpt_icon":0},{"id":"2584482836","title":"和元生物（688238）新增【基因编辑】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2584482836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584482836?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:27","pubTimestamp":1763368074,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，11月17日和元生物新增概念。和元生物主营业务：专注于为基因治疗的基础研究提供基因治疗载体研制、基因功能研究等CRO服务,以及为基因药物的研发提供IND-CMC药学研究、临床样品GMP生产等CDMO服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700020691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2583343654","title":"每周股票复盘：和元生物（688238）补选杨兴林为非独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2583343654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583343654?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:28","pubTimestamp":1763238492,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，和元生物报收于7.94元，较上周的7.37元上涨7.73%。本周关注点公司公告汇总：和元生物2025年第四次临时股东会选举杨兴林为非独立董事、计小青为独立董事。和元生物于2025年11月13日召开2025年第四次临时股东会，审议通过补选第四届董事会非独立董事及变更独立董事的议案。杨兴林当选为非独立董事，计小青当选为独立董事。出席会议股东64名，代表表决权27.4322%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2583591165","title":"和元生物（688238）披露补选董事会成员及变更独立董事公告，11月13日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583591165","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583591165?lang=zh_cn&edition=full","pubTime":"2025-11-13 23:00","pubTimestamp":1763046041,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，和元生物报收于7.82元，较前一交易日上涨1.56%，最新总市值为50.75亿元。该股当日开盘7.75元，最高7.83元，最低7.54元，成交额达1.54亿元，换手率为3.13%。公司近日发布公告称，于2025年11月13日召开2025年第四次临时股东会，审议通过了补选第四届董事会非独立董事及变更独立董事的议案。公告显示，杨兴林当选为公司非独立董事，计小青当选为独立董事。出席会议的股东共64名，代表表决权股份总数占公司有表决权股份总数的27.4322%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2582861123","title":"每周股票复盘：和元生物（688238）将补选董事及独董","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861123","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861123?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:00","pubTimestamp":1762632029,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，和元生物报收于7.37元，较上周的7.49元下跌1.6%。本周关注点公司公告汇总：和元生物将补选第四届董事会非独立董事及更换独立董事。公司公告汇总和元生物技术（上海）股份有限公司将于2025年11月13日召开第四次临时股东会，审议补选第四届董事会非独立董事及变更独立董事事项。王富杰因个人身体健康原因辞去非独立董事及审计委员会委员职务，董事会提名杨兴林为非独立董事候选人，任期至第四届董事会任期届满。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2581081559","title":"【机构调研记录】南华基金调研和元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081559?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:05","pubTimestamp":1762387515,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月5日披露的机构调研信息，南华基金近期对1家上市公司进行了调研，相关名单如下：1）和元生物 个股亮点：公司依托生成式AI赋能序列设计创新，构建了基于Transformer、Diffusion等深度学习框架的序列评分和序列生成的AI模型南华基金成立于2016年，截至目前，资产管理规模217.23亿元，排名120/211；资产管理规模217.23亿元，排名101/211；管理公募基金数36只，排名116/211；旗下公募基金经理9人，排名112/211。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600004937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2581081560","title":"【私募调研记录】域秀资产调研赛恩斯、和元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081560?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:04","pubTimestamp":1762387490,"startTime":"0","endTime":"0","summary":"根据市场公开信息及11月5日披露的机构调研信息，知名私募域秀资产近期对2家上市公司进行了调研，相关名单如下：1）赛恩斯 调研纪要：2025年前三季度公司营收约6.77亿元，同比增长15.81%，扣非净利润7196万元，同比下降10.78%。福建龙立化学2024年营收约1.5亿元，净利润约3800万元，经营符合预期。毛利率与净利率下降主要因费用增长及坏账计提增加。域秀资本致力于为客户提供多策略、优质的资产管理方案，持续为客户创造最大价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025110600004906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688480","BK0218","688238","BK0216"],"gpt_icon":0},{"id":"2580582667","title":"和元生物（688238）披露拟补选非独立董事及变更独立董事事项，11月04日股价下跌3.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580582667","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580582667?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:32","pubTimestamp":1762266746,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，和元生物报收于7.47元，较前一交易日下跌3.98%，最新总市值为48.48亿元。该股当日开盘7.77元，最高7.8元，最低7.43元，成交额达1.19亿元，换手率为2.45%。近日，和元生物技术（上海）股份有限公司发布公告称，公司将于2025年11月13日召开第四次临时股东会，审议补选第四届董事会非独立董事及变更独立董事事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400039625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2580747477","title":"每周股票复盘：和元生物（688238）股东户数增11.44%，三季报营收降14.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580747477","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580747477?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:14","pubTimestamp":1762035255,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，和元生物报收于7.49元，较上周的7.53元下跌0.53%。业绩披露要点：2025年第三季度主营收入6049.86万元，同比下降14.56%。股本股东变化截至2025年9月30日，公司股东户数为1.4万户，较6月30日增加1442户，增幅11.44%。公司公告汇总2025年第三季度报告显示，研发投入本报告期1144.78万元，同比增长13.70%；年初至报告期末3466.12万元，同比减少11.47%。总资产21.17亿元，较上年度末减少7.34%；归属于上市公司股东的所有者权益14.81亿元，较上年度末减少14.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238"],"gpt_icon":0},{"id":"2579917934","title":"股市必读：和元生物三季报 - 第三季度单季净利润同比增长24.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579917934","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579917934?lang=zh_cn&edition=full","pubTime":"2025-10-29 08:45","pubTimestamp":1761698704,"startTime":"0","endTime":"0","summary":"来自业绩披露要点：2025年前三季度公司归母净利润为-1.62亿元，同比上升14.57%。财务报告和元生物2025年三季报显示，公司主营收入1.8亿元，同比下降1.91%；归母净利润-1.62亿元，同比上升14.57%；扣非净利润-1.62亿元，同比上升19.03%。2025年第三季度单季度主营收入6049.86万元，同比下降14.56%；单季度归母净利润-5754.32万元，同比上升24.7%；单季度扣非净利润-5771.64万元，同比上升28.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251029/31746057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688238"],"gpt_icon":0},{"id":"2579584915","title":"和元生物（688238）2025年三季报简析：亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579584915","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579584915?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:17","pubTimestamp":1761689873,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期和元生物发布2025年三季报。截至本报告期末，公司营业总收入1.8亿元，同比下降1.91%，归母净利润-1.62亿元，同比上升14.57%。按单季度数据看，第三季度营业总收入6049.86万元，同比下降14.56%，第三季度归母净利润-5754.32万元，同比上升24.7%。本报告期和元生物盈利能力上升，毛利率同比增幅23.68%，净利率同比增幅13.18%。），公司上市来已有年报2份，亏损年份4次，如无借壳上市等因素，价投一般不看这类公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900008855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2578693459","title":"和元生物（688238）披露2025年第三季度报告，10月28日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578693459","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578693459?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:01","pubTimestamp":1761645697,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，和元生物报收于7.58元，较前一交易日下跌0.39%，最新总市值为49.2亿元。近日，和元生物发布2025年第三季度报告。公告显示，公司本报告期实现营业收入60,498,633.08元，较上年同期减少14.56%；年初至报告期末累计实现营业收入180,353,622.06元，同比下降1.91%。归属于上市公司股东的净利润方面，本报告期为-57,543,183.53元，年初至报告期末为-162,113,304.23元。截至报告期末，公司总资产为2,116,971,711.57元，较上年度末减少7.34%；归属于上市公司股东的所有者权益为1,481,419,704.38元，较上年度末下降14.85%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800033680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2578924936","title":"和元生物(688238)9月30日股东户数1.4万户，较上期增加11.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578924936","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578924936?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:23","pubTimestamp":1761643437,"startTime":"0","endTime":"0","summary":"证券之星消息，近日和元生物披露，截至2025年9月30日公司股东户数为1.4万户，较6月30日增加1442.0户，增幅为11.44%。户均持股数量由上期的5.15万股减少至4.62万股，户均持股市值为36.36万元。在医疗服务行业个股中，和元生物股东户数低于行业平均水平，截至9月30日，医疗服务行业平均股东户数为4.67万户。从股价来看，2025年6月30日至2025年9月30日，和元生物区间涨幅为26.94%，在此期间股东户数增加1442.0户，增幅为11.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800031227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2578662244","title":"图解和元生物三季报：第三季度单季净利润同比增长24.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578662244","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578662244?lang=zh_cn&edition=full","pubTime":"2025-10-28 02:36","pubTimestamp":1761590210,"startTime":"0","endTime":"0","summary":"证券之星消息，和元生物2025年三季报显示，公司主营收入1.8亿元，同比下降1.91%；归母净利润-1.62亿元，同比上升14.57%；扣非净利润-1.62亿元，同比上升19.03%；其中2025年第三季度，公司单季度主营收入6049.86万元，同比下降14.56%；单季度归母净利润-5754.32万元，同比上升24.7%；单季度扣非净利润-5771.64万元，同比上升28.7%；负债率30.03%，投资收益-23.74万元，财务费用422.04万元，毛利率-16.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800002115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238"],"gpt_icon":0},{"id":"2566352089","title":"【机构调研记录】嘉实基金调研剑桥科技、和元生物等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2566352089","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566352089?lang=zh_cn&edition=full","pubTime":"2025-09-11 08:04","pubTimestamp":1757549067,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月10日披露的机构调研信息，嘉实基金近期对3家上市公司进行了调研，相关名单如下：1）剑桥科技 调研纪要：公司展出多款800G和1.6T光模块产品，并加快扩产速度，明年产能目标提升，以800G为主，1.6T逐步量产。2024年海外收入3.16亿元，2025年上半年达2.42亿元，毛利率持续提升并实现扭亏为盈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100005730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0214","603083","BK0216"],"gpt_icon":0},{"id":"2566935731","title":"【机构调研记录】兴业基金调研和元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2566935731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566935731?lang=zh_cn&edition=full","pubTime":"2025-09-11 08:04","pubTimestamp":1757549058,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为兴业研究精选混合A，最新单位净值为1.79，近一年增长77.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100005717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2564811844","title":"9月1日和元生物发布公告，股东减持97万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564811844","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564811844?lang=zh_cn&edition=full","pubTime":"2025-09-01 19:01","pubTimestamp":1756724490,"startTime":"0","endTime":"0","summary":"证券之星消息，9月1日和元生物发布公告《和元生物:股东减持股份计划时间届满暨减持股份结果公告》，其股东浙江华睿盛银创业投资有限公司、诸暨富华产业转型升级基金合伙企业、浙江华睿火炬创业投资合伙企业、浙江华睿胡庆余堂健康产业投资基金合伙企业、杭州华睿嘉银股权投资合伙企业于2025年8月16日至2025年8月27日间合计减持97.0万股，占公司目前总股本的0.1494%，变动期间该股股价下跌0.37%，截止8月27日收盘报7.98元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100028752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2563838880","title":"每周股票复盘：和元生物（688238）上半年营收增6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563838880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563838880?lang=zh_cn&edition=full","pubTime":"2025-08-31 06:32","pubTimestamp":1756593150,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，和元生物报收于7.77元，较上周的8.05元下跌3.48%。本周，和元生物8月25日盘中最高价报8.82元。本周关注点来自业绩披露要点：2025年上半年公司实现营业收入11,985.50万元，同比增长6.01%。CRO销售收入4,069.98万元，同比增长3.79%；CDMO销售收入6,561.67万元，新增CDMO业务订单超过9,000万元。答：2025年上半年，公司研发支出2,321.34万元，占营业收入比例为19.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238"],"gpt_icon":0},{"id":"2562775757","title":"股市必读：和元生物（688238）8月27日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2562775757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562775757?lang=zh_cn&edition=full","pubTime":"2025-08-28 06:22","pubTimestamp":1756333379,"startTime":"0","endTime":"0","summary":"截至2025年8月27日收盘，和元生物报收于7.98元，下跌4.43%，换手率3.52%，成交量22.55万手，成交额1.85亿元。机构调研要点：2025年上半年，和元生物实现营业收入11,985.50万元，同比增长6.01%，归属于母公司所有者的扣除非经常性损益的净利润为-10,451.18万元，较上年同期减少亏损1,489.73万元。公司2025年上半年的研发投入情况2025年上半年，公司研发支出2,321.34万元，占营业收入比例为19.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800006144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2562574769","title":"【机构调研记录】南华基金调研和元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2562574769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562574769?lang=zh_cn&edition=full","pubTime":"2025-08-27 08:02","pubTimestamp":1756252933,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月26日披露的机构调研信息，南华基金近期对1家上市公司进行了调研，相关名单如下：1）和元生物 个股亮点：公司依托生成式AI赋能序列设计创新，构建了基于Transformer、Diffusion等深度学习框架的序列评分和序列生成的AI模型南华基金成立于2016年，截至目前，资产管理规模215.11亿元，排名120/210；资产管理规模215.11亿元，排名102/210；管理公募基金数34只，排名117/210；旗下公募基金经理8人，排名118/210。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700011045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766376736884,"stockEarnings":[{"period":"1week","weight":0.0148},{"period":"1month","weight":-0.0716},{"period":"3month","weight":-0.1181},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.2246},{"period":"ytd","weight":0.3907}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0184},{"period":"6month","weight":0.1579},{"period":"1year","weight":0.1544},{"period":"ytd","weight":0.1607}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"和元生物技术(上海)股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"14047人(较上一季度增加11.44%)","perCapita":"45642股","listingDate":"2022-03-22","address":"上海市浦东新区国际医学园区紫萍路908弄19号楼","registeredCapital":"64903万元","survey":" 和元生物技术(上海)股份有限公司的主营业务是细胞和基因治疗CRO/CDMO业务。公司的主要产品是基因治疗载体研制服务、基因功能研究服务、基因检测服务、新药Pre-IND服务、新药Post-IND服务、临床III期生产服务、商业化生产服务、Post-IND配套服务、再生医学制备服务、细胞存储及配套服务、生物原料、生物制剂产品、试剂、试剂盒及其他产品。","listedPrice":13.23},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和元生物(688238)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和元生物(688238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和元生物,688238,和元生物股票,和元生物股票老虎,和元生物股票老虎国际,和元生物行情,和元生物股票行情,和元生物股价,和元生物股市,和元生物股票价格,和元生物股票交易,和元生物股票购买,和元生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和元生物(688238)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和元生物(688238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}